Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 17/20 | 0.80 |
| ▸ | HTR2C | P28335 | 7/20 | 0.80 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.60 |
| ▸ | HTR2A | P28223 | 4/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2926522 | 0.99 | MCHR1 (0.78) | MCHR1HTR2CCHRM1HTR2ACYP2D6 | |
| SCHEMBL2926180 | 0.88 | MCHR1 (0.82) | MCHR1HTR2CCHRM1HTR2ACYP2D6 | |
| SCHEMBL2921113 | 0.87 | MCHR1 (0.80) | MCHR1HTR2CCHRM1HTR2ACYP2D6 | |
| SCHEMBL5648064 | 0.86 | MCHR1 (1.00) | MCHR1HTR2CCYP2D6MLLT1ALDH1A1 | |
| SCHEMBL5647227 | 0.85 | MCHR1 (0.98) | MCHR1HTR2CCYP2D6MLLT1ALDH1A1 | |
| SCHEMBL28663251 | 0.84 | RAB9A (0.76) | MCHR1HTR2CCHRM1HTR2ACYP2D6 | |
| SCHEMBL22079996 | 0.84 | RAB9A (0.76) | MCHR1HTR2CCHRM1HTR2ACYP2D6 | |
| SCHEMBL6313332 | 0.84 | MCHR1 (0.71) | MCHR1HTR2CNPC1RAB9A | |
| SCHEMBL6306094 | 0.84 | MCHR1 (0.58) | MCHR1HTR2CNPC1RAB9A | |
| SCHEMBL2925651 | 0.83 | MCHR1 (0.81) | MCHR1HTR2CCYP2D6MLLT1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040077628-A1 | Melanin-concentrating hormone antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-22 | — | — | US | claimed |
| EP-1285651-A1 | MELANIN CONCENTRATING HORMONE ANTAGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2003-02-26 | — | — | EP | claimed |
| EP-1285651-B1 | MELANIN CONCENTRATING HORMONE ANTAGONISTS | TAKEDA PHARMACEUTICAL (JP) | 2010-09-01 | — | — | EP | disclosed |
| EP-1285651-B1 | MELANIN CONCENTRATING HORMONE ANTAGONISTS | TAKEDA PHARMACEUTICAL (JP) | 2010-09-01 | — | — | EP | disclosed |
| US-6930185-B2 | Melanin-concentrating hormone antagonist | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-08-16 | — | — | US | disclosed |
| US-20040077628-A1 | Melanin-concentrating hormone antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-22 | — | — | US | disclosed |
| EP-1285651-A1 | MELANIN CONCENTRATING HORMONE ANTAGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2003-02-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077628-A1 | Melanin-concentrating hormone antagonist | MCHR1, MC1R, MCHR2 | MCHR1 1/4885HTR2C 107/4885CHRM1 656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.